Refine
Year of publication
Language
- English (852)
Has Fulltext
- yes (852)
Is part of the Bibliography
- no (852)
Keywords
- Heavy Ion Experiments (20)
- Hadron-Hadron scattering (experiments) (11)
- Hadron-Hadron Scattering (5)
- Heavy-ion collision (5)
- Collective Flow (4)
- Quark-Gluon Plasma (4)
- Jets (3)
- Jets and Jet Substructure (3)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Heavy Quark Production (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- genomics (2)
- ALICE detector (1)
- Agaricales (1)
- Anti-nuclei (1)
- Basidiomycetes (1)
- Brassicales (1)
- Carbohydrate active enzymes (1)
- Centrality Class (1)
- Centrality Selection (1)
- Collective Flow, (1)
- Comparative genomics (1)
- Developmental biology (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Fibre/foam sandwich radiator (1)
- Fruit body (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hard Scattering (1)
- Heavy Ion Experiment (1)
- Invariant Mass Distribution (1)
- Ionisation energy loss (1)
- LHC (1)
- Microthlaspi erraticum (1)
- Minimum Bias (1)
- Monte Carlo (1)
- Multi-Parton Interactions (1)
- Multi-wire proportional drift chamber (1)
- Mushroom (1)
- Neural network (1)
- Pb–Pb collisions (1)
- Photorhabdus (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- QCD (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Rapidity Range (1)
- Relativistic heavy-ion collisions (1)
- Resolution Parameter (1)
- Secondary metabolites (1)
- Sequencing (1)
- Symbiosis (1)
- Systematic Uncertainty (1)
- TR (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transition radiation detector (1)
- Trigger (1)
- Vector Boson Production (1)
- White-rot (1)
- Xenon-based gas mixture (1)
- bone marrow microenvironment (1)
- chronic myeloid leukemia (1)
- combination therapies (1)
- dE/dx (1)
- evolution (1)
- forest tree (1)
- fungi (1)
- hardwood (1)
- heavy ion experiments (1)
- history (1)
- hybrid assembly (1)
- magnesium transporters (1)
- metabolism (1)
- quark gluon plasma (1)
- targeted therapy (1)
- transcriptomics (1)
Institute
- Physik (845)
- Frankfurt Institute for Advanced Studies (FIAS) (787)
- Informatik (753)
- Institut für Ökologie, Evolution und Diversität (4)
- Biodiversität und Klima Forschungszentrum (BiK-F) (3)
- Informatik und Mathematik (3)
- Medizin (3)
- Senckenbergische Naturforschende Gesellschaft (3)
- Hochschulrechenzentrum (2)
- Biochemie und Chemie (1)
Chronic myeloid leukemia (CML) has been a “model disease” with a long history. Beginning with the first discovery of leukemia and the description of the Philadelphia Chromosome and ending with the current goal of achieving treatment-free remission after targeted therapies, we describe here the journey of CML, focusing on molecular pathways relating to signaling, metabolism and the bone marrow microenvironment. We highlight current strategies for combination therapies aimed at eradicating the CML stem cell; hopefully the final destination of this long voyage.
Therapy resistance in leukemia may be due to cancer cell-intrinsic and/or -extrinsic mechanisms. Mutations within BCR-ABL1, the oncogene giving rise to chronic myeloid leukemia (CML), lead to resistance to tyrosine kinase inhibitors (TKI), and some are associated with clinically more aggressive disease and worse outcome. Using the retroviral transduction/transplantation model of CML and human cell lines we faithfully recapitulate accelerated disease course in TKI resistance. We show in various models, that murine and human imatinib-resistant leukemia cells positive for the oncogene BCR-ABL1T315I differ from BCR-ABL1 native (BCR-ABL1) cells with regards to niche location and specific niche interactions. We implicate a pathway via integrin β3, integrin-linked kinase (ILK) and its role in deposition of the extracellular matrix (ECM) protein fibronectin as causative of these differences. We demonstrate a trend towards a reduced BCR-ABL1T315I+ tumor burden and significantly prolonged survival of mice with BCR-ABL1T315I+ CML treated with fibronectin or an ILK inhibitor in xenogeneic and syngeneic murine transplantation models, respectively. These data suggest that interactions with ECM proteins via the integrin β3/ILK-mediated signaling pathway in BCR-ABL1T315I+ cells differentially and specifically influence leukemia progression. Niche targeting via modulation of the ECM may be a feasible therapeutic approach to consider in this setting.